Brief: Neuren Pharmaceuticals Says Prader-Willi Syndrome IND For NNZ-2591 Approved By FDA
23/01/2023 01:07
Jan 23 (Reuters) - Neuren Pharmaceuticals Ltd NEU.AX :
* PRADER-WILLI SYNDROME IND FOR NNZ-2591 APPROVED BY FDA
* U.S. FDA GIVES APPROVAL FOR NEUREN TO PROCEED WITH PLANNED
PHASE
2 CLINICAL TRIAL IN CHILDREN WITH PRADER-WILLI SYNDROME
Source text for Eikon: ID:nASX81j9qk
Further company coverage: NEU.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neuren Pharmaceuticals
See all newsAustralia's Neuren set for weekly gain on FDA nod, drug forecast upgrade
Australia's Neuren Pharmaceuticals gains on upbeat FY trofinetide earnings outlook
Australia's Neuren Pharma rises as US FDA grants orphan tag for NNZ-2591
Strong partner sales propel Neuren Pharmaceuticals to top of Australia benchmark
Brief: Neuren Pharmaceuticals Says DAYBU Recommended For Approval In European Union